Terminology Service for NFDI4Health
All terms in CHEBI
| Label | Id | Description |
|---|---|---|
| PG(16:1(9Z)/18:1(9Z)) | CHEBI_89093 | |
| PC(20:1(11Z)/P-16:0) | CHEBI_89094 | |
| PC(20:2(11Z,14Z)/14:0) | CHEBI_89095 | |
| PC(20:2(11Z,14Z)/14:1(9Z)) | CHEBI_89096 | |
| PC(20:1(11Z)/22:0) | CHEBI_89097 | |
| PC(20:1(11Z)/22:1(13Z)) | CHEBI_89098 | |
| urolithin A 3-O-glucuronide | CHEBI_89099 | [A member of the class of benzochromenones that is urolithin A in which the phenolic hydrogen at position 3 has been replaced by a beta-D-glucuronosyl group.] |
| CHEBI_5504 | CHEBI_5504 | |
| CHEBI_5505 | CHEBI_5505 | |
| CHEBI_5506 | CHEBI_5506 | |
| CHEBI_5507 | CHEBI_5507 | |
| Glycyl amino acid | CHEBI_5500 | |
| CHEBI_5503 | CHEBI_5503 | |
| 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-3-yl 6-O-(6-deoxyhexopyranosyl)hexopyranoside | CHEBI_139410 | |
| Kaempferol-3-glucoside-3''-rhamnoside | CHEBI_139411 | |
| alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc | CHEBI_139412 | [An amino oligosaccharide that is a branched undecasaccharide derivative consisting of a heptasaccharide chain of alpha-sialyl, beta-D-galactose, N-acetyl-beta-D-glucosamine, alpha-D-mannose, beta-D-mannose, and two N-acetyl-beta-D-glucosamine residues linked sequentially (2->3), (1->4), (1->2), (1->3), (1->4) and (1->4), to the beta-D-mannose residue of which is (1->6)-linked a beta-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-alpha-D-mannosyl tetrasaccharide branch and to the reducing end N-acetyl-beta-D-glucosamine residue of which is (1->6)-linked an alpha-L-fucose residue. When it is the N-glycan content of the tumour necrosis factor (TNF) alpha blocker cetuximab, the terminal Neu5Ac residue may be replaced by Neu5Gc, while the fucose residue may be absent. When it is the N-glycan content of the tumour necrosis factor (TNF) alpha blocker infliximab, the terminal Neu5Ac residue may be replaced by Neu5Gc, while one or both of the fucose and terminal galactose residues may be absent.] |
| N-glycan derivative | CHEBI_71275 | [The term used to refer to the 'carbohydrate' portion of N-glycoproteins when attached to a nitrogen from asparagine or arginine side-chains, when this portion is a carbohydrate derivative.] |
| 1-oleoyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate | CHEBI_139413 | [A 1,2-diacyl-sn-glycerol 3-phosphate in which the 1- and 2-acyl substituent are specified as oleoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively; major species at pH 7.3.] |
| 1-oleoyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate(2-) | CHEBI_138723 | [A 1,2-diacyl-sn-glycerol 3-phosphate(2-) in which the 1- and 2-acyl substituent are specified as oleoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively; major species at pH 7.3.] |
| 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-3-yl 2-O-hexopyranosylhexopyranoside | CHEBI_139414 |